- A groundbreaking trial for a new human bird flu vaccine, mRNA-1018 developed by Moderna, has commenced in the UK and US.
- The phase 3 study aims to proactively address the growing threat of the A(H5N1) strain, with experts warning of the potential for human-to-human transmission.
- Approximately 4,000 individuals, including 3,000 in the UK, are expected to enrol, with particular encouragement for poultry farmers and those in close contact with birds.
- The vaccine utilises mRNA technology, similar to Covid-19 jabs, and early trials showed it was generally well tolerated and induced a strong immune response.
- Researchers highlight the advantage of mRNA vaccines for their faster production and adaptability to new strains, offering a crucial tool for pandemic preparedness.
IN FULL
